Supriya Lifescience LimitedUnclassifiedSUPRIYA
Q1 FY27 earnings callSupriya Lifescience Limited
Revenue grew 31% year-on-year, but EBITDA margin contracted to 25% due to temporary water scarcity and one-off solar policy costs, though management remains confident in its full-year revenue and margin guidance.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | Rs. 190 crores | 31% | |
| EBITDA | Rs. 47 crores | -8.1% | |
| EBITDA Margin | 25% | — | |
| PAT | Rs. 24 crores | — | |
| Exports Contribution | 81% | — | |
| Backward Integration | 72% | — |
Financials
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹185.65 Cr+32.5% YoY+11.8% QoQ | ₹46.78 Cr+57% YoY+1.4% QoQ | ₹5.82+57.3% YoY+1.9% QoQ |
| Q2 FY25 | ₹166.10 Cr+18.6% YoY+3.4% QoQ | ₹46.15 Cr+93.3% YoY+3.4% QoQ | ₹5.71+92.3% YoY+3.1% QoQ |
| Q1 FY25 | ₹160.63 Cr+21.7% YoY+1.5% QoQ | ₹44.64 Cr+56.6% YoY+20.9% QoQ | ₹5.54+56.5% YoY+20.7% QoQ |
| Q4 FY24 | ₹158.18 Cr+11.2% YoY+12.9% QoQ | ₹36.93 Cr-3.4% YoY+24% QoQ | ₹4.59-3.4% YoY+24.1% QoQ |
| Q3 FY24 | ₹140.07 Cr+33.2% YoY0% QoQ | ₹29.79 Cr+212.9% YoY+24.7% QoQ | ₹3.70+213.6% YoY+24.6% QoQ |
TL;DR
- Revenue of Rs 190 crores, up 31% YoY, with strong export demand.
- EBITDA fell 8.1% YoY to Rs 47 crores, margin at 25% impacted by water shortage and one-off power cost.
- Water scarcity led to deferment of Rs 35 crores in sales; issue now resolved.
- Solar policy change resulted in a one-time retrospective cost of ~Rs 4.5-5 crores at EBITDA level.
- Maintains guidance of ~Rs 1,000 crores revenue and 33-35% EBITDA margin for FY27.
- Expects stronger ramp-up in H2 FY27 from new launches and Ambernath facility.
Said on the call
“Excluding these one-off impacts, margins would have remained within our guided range.”
From the Q&A
| Topic | What management said |
|---|---|
| Margins and One-off Costs | Management clarified the solar policy change led to a one-time retrospective cost of ~Rs 4.5-5 crores; the water scarcity issue, which caused Rs 35 crores deferred sales, is resolved and not expected to recur. |
| Patalganga (Isambe) Project | Construction of boundary walls has started; Phase-1 CapEx is Rs 200 crores focused on API blocks, with ~40% completion expected in 2.5 years. |
| Ambernath Facility and Audit | Received dates for EU audit in second half of November 2026; expects it to open up regulated market revenue. |
| Customs and Narcotics Issue | A small-value consignment is under investigation due to a technical lapse where an export authorization expired two days before shipping; a new authorization has been received, and the matter is sub judice. |
| High Inventory | Inventory is Rs 230-240 crores, built up for a planned shutdown that has now been deferred; will be liquidated over the next 3-4 quarters. |
| Guidance Confidence | Management reiterated confidence in achieving ~Rs 1,000 crores revenue and 33-35% EBITDA margin for FY27, expecting to recover Q1's lost sales over coming quarters. |
| CMO/CDMO Progress | Close to signing a term sheet for a large anesthetic CDMO contract; making progress on several other API and finished formulation CDMO opportunities. |
| Growth Trajectory | Sees potential for growth beyond the stated 20% CAGR driven by new products, verticals, and capacity building, though dependent on regulatory approvals. |
Guidance
- Revenue target of ~Rs 1,000 crores for FY27 remains on track.
- EBITDA margin guidance of 33% to 35% for FY27 is maintained.
- Expects stronger ramp-up in the second half of FY27.
- Targets a 20% year-on-year CAGR growth trajectory with potential for more.
Source
Summary written from the transcript filed by Supriya Lifescience Limited for the call held on 14 Aug 2026; published 18 Aug 2026, 21:19 IST.